What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

 

 

VitaK will launch a new generation of E-health solutions, including apps for IOS and Android devices, to support home care nurses and general practitioners. One of them is the StiffnoGraph E-health.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com